Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort study

Abstract

Baveno VII criteria (B7C) and Baveno VI criteria (B6C) have been widely used to estimate the risk of hepatic decompensation. However, the impact of age on these criteria warrants further investigation. The international, multicenter cohort study included 1138 patients with compensated cirrhosis (median follow-up of 40.6 months), aiming to evaluate the value of age in predicting hepatic decompensation. We identified age as an independent predictor of hepatic decompensation, with 60 years determined as the optimal cut-off value. The occurrence of decompensation was 18.7% and 6.7% in the older (age ≥60 years) and younger (age <60 years) groups, respectively (p < 0.001). We subsequently integrated age into the existing Baveno criteria. In patients not meeting Baveno criteria (defined as not meeting B6C or B7C), the older group exhibited a significantly elevated risk of decompensation compared to the younger group (p < 0.05). However, no significant difference was observed between the older and younger groups in patients meeting Baveno criteria (p > 0.05). In conclusion, our study demonstrated that integrating age into the Baveno criteria could enhance the assessment of hepatic decompensation. Age should be considered before discharging patients with compensated cirrhosis from the surveillance of hepatic decompensation.

Keywords

age / Baveno criteria / compensated cirrhosis / hepatic decompensation

References

[1] Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021; 398(10308): 1359-1376.

[2] Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023; 79(2): 516-537.

[3] Wortham A, Khalifa A, Rockey DC. The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient. Port Hypertens Cirrhos. 2022; 1(2): 101-106.

[4] de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63(3): 743-752.

[5] D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44(1): 217-231.

[6] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020; 5(3): 245-266.

[7] Wang K, Tian M, Zhang L, Liu S, Guo X, Ma J. Hepatic venous pressure gradient measurement guiding nonselective beta-blocker therapy in a patient with clinically significant portal hypertension. Port Hypertens Cirrhos. 2023; 2(2): 105-108.

[8] Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018; 3(10): 708-719.

[9] de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII—Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4): 959-974.

[10] Zhao L, Wang T, Guo C, et al. Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis. Hepatol Int. 2022; 16(4): 936-943.

[11] Wong YJ, Zhaojin C, Tosetti G, et al. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients. Clin Mol Hepatol. 2022; 29(1): 135-145.

[12] Global hepatitis report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

[13] Integrated Care for Older People (ICOPE): Guidance for Person-Centred Assessment and Pathways in Primary Care. Geneva: World Health Organization; 2019 (WHO/FWC/ALC/19.1). Licence: CC BY-NC-SA 3.0 IGO.

[14] Frith J, Jones D, Newton JL. Chronic liver disease in an ageing population. Age Ageing. 2009; 38(1): 11-18.

[15] Fox M, Fox J, Davies M. Diagnosis and management of chronic liver disease in older people. Rev Clinl Gerontol. 2011; 21(1): 1-15.

[16] Wynne HA, James OF. The ageing liver. Age Ageing. 1990; 19(1): 1-3.

[17] Wakkerman FC, Wu J, Putter H, et al. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials. Lancet Oncol. 2024; 25(6): 779-789.

[18] Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2016; 2(3): 313-320.

[19] Pitisuttithum P, Treeprasertsuk S. Nonalcoholic fatty liver disease (NAFLD) among older adults. Port Hypertens Cirrhos. 2022; 1(3): 184-191.

[20] de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992; 103(5): 1630-1635.

[21] Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. an analysis of 379 patients. Ann Intern Med. 1984; 101(5): 613-616.

[22] Lin H, Yip TC-F, Zhang X, et al. Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. Hepatology. 2023; 77(2): 573-584.

[23] Zhang X, Wong GL-H, Yip TC-F, et al. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology. 2022; 76(5): 1409-1422.

[24] Jothimani D, Rela M, Kamath PS. Management of portal hypertension in the older patient. Curr Gastroenterol Rep. 2024; 26(9): 231-240.

[25] Sheedfar F, Di Biase S, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes?. Aging Cell. 2013; 12(6): 950-954.

[26] Harraz OF, Jensen LJ. Aging, calcium channel signaling and vascular tone. Mech Ageing Dev. 2020; 191: 111336.

[27] Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015; 385(9967): 549-562.

[28] El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Relationship between heart disease and liver disease: a two-way street. Cells. 2020; 9(3): 567.

[29] Lee DH, Keum N, Hu FB, et al. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. BMJ. 2018; 362: k2575.

[30] Qu Y, Emoto K, Eguchi T, et al. Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. J Thorac Oncol. 2019; 14(3): 482-493.

[31] Tranah TH, Ballester M-P, Carbonell-Asins JA, et al. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. J Hepatol. 2022; 77(6): 1554-1563.

[32] Diaz AA, Wang W, Orejas JL, et al. Suspected bronchiectasis and mortality in adults with a history of smoking who have normal and impaired lung function: a cohort study. Ann Intern Med. 2023; 176(10): 1340-1348.

[33] Denz R, Klaaßen-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. Stat Med. 2023; 42(10): 1461-1479.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.